Amneal Pharmaceuticals (AMRX) executive compensation, 2026 proxy

Chintu Patel, Co-Chief Executive Officer, was paid $8.7M in 2025, up 21% from $7.2M the year before. The CEO-to-median-employee pay ratio was 679:1, on median employee pay of $12,853.

Filed
March 25, 2026
Annual meeting
May 6, 2026
Pay year
2025
Named executives
6
CEO total pay
$8.7M+21% vs prior year
CEO to median employee
679:1median $12,853
CEO pay in equity
80%$7M in awards
Prior say-on-pay support
99%of votes cast
Revenue Growth
8.0%Compared to 2024 results
Adjusted EBITDA
$688MUp 10.0% from 2024
Net Leverage
3.5xDown from 7.4x in 2019

How Patel was paid

$8.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary9%Stock awards80%Non-equity incentive10%All other compensation1%

Named executive officers

ExecutiveTotal
Chirag PatelCo-Chief Executive Officer and President$8,691,745
Chintu PatelCo-Chief Executive Officer$8,730,545
Anastasios KonidarisEVP & Chief Financial Officer$3,293,494
Andrew BoyerEVP, Chief Commercial Officer - Generics$3,017,163
Nikita ShahEVP, Chief Human Resources Officer$2,730,582
Jason DalyEVP, Chief Legal Officer & Secretary$2,860,442

What changed and why

  • $3,019MNet revenue increased 8.0% to $3,019 million compared to 2024.
  • $688MAdjusted EBITDA grew 10.0% to $688 million in fiscal 2025.
  • $8.7MCo-CEO total compensation increased to $8,730,545 for Chintu Patel.
  • 99.4%The advisory say-on-pay vote received 99.4% support at the prior annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.